Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.1.1.21: aldose reductase

This is an abbreviated version!
For detailed information about aldose reductase, go to the full flat file.

Word Map on EC 1.1.1.21

Reaction

alditol
+
NAD(P)+
=
aldose
 +
NAD(P)H
 +
H+

Synonyms

17betaHSD5, 20-alpha-HSD, 20-alpha-hydroxysteroid dehydrogenase, AdhA, AKR1B, AKR1B1, AKR1B10, AKR1B13, AKR1B14, AKR1B3, AKR1C3, AKR4C7, aldehyde reductase, alditol/NADP+ oxidoreductase, alditol: NADP+ 1-oxidoreductase, alditol:NAD(P)+1oxidoreductase, alditol:NADP 1-oxidoreductase, alditol:NADP oxidoreductase, aldo-keto reductase, aldo-keto reductase family 1 member B1, aldo-keto reductase family 1 member B7, aldoketo reductase 1C3, aldose reductase, aldose reductase 2, aldose reductase-like, aldose reductase-like protein, aldose xylose reductase, ALDRXV4, ALR, ALR1, ALR2, AR, ARI, BAR, EC 1.1.1.139, Fibroblast growth factor regulated protein, FR-1 protein, GRE3, HAR, HRAR, isobutyraldehyde reductase, More, MVDP, NADPH dependent xylose reductase, NADPH-aldopentose reductase, NADPH-aldose reductase, polyol dehydrogenase (NADP2), RLAR, small intestine reductase, TPN-polyol dehydrogenase, VAS deferens androgen-dependent protein, YqhD

ECTree

     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
                1.1.1.21 aldose reductase

Inhibitors

Inhibitors on EC 1.1.1.21 - aldose reductase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
((1-(2H-tetrazol-5-yl)methyl)-1H-pyrrol-3-yl)(phenyl)-methanone
-
40% inhibition
((3aR,4R,6S,6aR)-6-((Z)-(((4-hydroperoxybenzyl)oxy)imino)methyl)-4-hydroxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 3-chlorobenzoate
83% inhibition at 0.1 mM, oxyimino derivative, obtained by reaction of a 1,5-dicarbonyl substrate with O-(arylmethyl)hydroxylamine. Inhibitor reduces both cell death and the apoptotic process when tested in an in vitro model of diabetic retinopathy
(1,1-dihydroxy-3-oxo-1,3-dihydro-2H-1,2-benzisothiazol-2-yl)acetic acid
i.e. BiT, 1,1-dioxide-benzo[d]isothiazol-3-one alkanoic acid derivatives
(1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazol-2-yl)acetic acid
IC50: 0.010 mM
(1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazol-2-yl)acetic acid ethyl ester
-
(1,3,3-trioxo-2,3-dihydronaphtho[2,3-d]isothiazol-2-yl)acetic acid ethyl ester
-
(1-(2-(2H-tetrazol-5-yl)ethyl)-1H-pyrrol-3-yl)(phenyl)-methanone
-
6% inhibition
(1-(2H-tetrazole-5-yl)-1H-pyrrol-2-yl)(phenyl)-methanone
-
-
(1-(2H-tetrazole-5-yl)-1H-pyrrol-3-yl)(phenyl)-methanone
-
-
(1-(3-(2H-tetrazol-5-yl)propyl)-1H-pyrrol-3-yl)(phenyl)-methanone
-
41% inhibition
(10-benzyl-3,4-dioxo-3,4-dihydro[1,2,4]triazino[4,3-a]benzimidazol-2(10H)-yl)acetic acid
-
(1H-indol-1-yl)acetic acid
-
(2,3-dihydrocyclopenta[b]indol-4(1H)-yl)acetic acid
-
(2,4-dioxo-5-[(6,8-dimethyl-4-oxo-4H-chromen-3-yl)methylene]-1,3-thiazolidine-3-yl) acetic acid
-
-
(2,4-dioxo-5-[(6-isopropyl-4-oxo-4H-chromen-3-yl)methylene]-1,3-thiazolidine-3-yl) acetic acid
-
-
(2,4-dioxo-5-[(6-methyl-4-oxo-4H-chromen-3-yl)methylene]-1,3-thiazolidine-3-yl)acetic acid
-
-
(2,4-dioxo-5-[(6-nitro-4-oxo-4H-chromen-3-yl)methylene]-1,3-thiazolidine-3-yl)acetic acid
-
-
(2-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)-acetic acid
-
an aldose reductase inhibitor and antioxidant of zwitterionic nature
(2-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole-8-yl)-acetic acid
-
uncompetitive with both D,L-glyceraldehyde and NADPH
(2-carbamoyl-5-fluorophenoxy)acetic acid
the carboxamide nitrogen can undergo a further H-bond to the additionally recruited water molecule W2 that in turn mediates H-bonded contacts involving the additional water molecule W3 to the amide bonds next to Leu300. Using water molecules W2 and W3 as mediating partners, the compound forms additional polar contacts to the protein
(2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetic acid
7fold selectivity for ALR2 over ALR1
(2-oxo-8-phenyl-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetic acid
-
(2-oxo-8-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetic acid
24fold selectivity for ALR2 over ALR1
(2-phenethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole-8-yl)-acetic acid
-
uncompetitive with both D,L-glyceraldehyde and NADPH
(2-[(4-bromo-2-fluorobenzyl)carbamoyl]-5-chlorophenoxy)acetic acid
thermodynamic binding data for isoform ALR2 and mutants
(2-[[2-(hydroxymethyl)phenyl]methyl]-3-oxo-2,3-dihydro-5H-[1,2,4]triazino[5,6-b]indol-5-yl)acetic acid
-
410fold selectivity for ALR2 over ALR1
(2E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
(2R)-1-[(benzyloxy)carbonyl]-2,3-dihydro-1H-indole-2-carboxylic acid
CC-13401
(2R)-2,3-dihydroxypropanamide
-
(2R)-2-hydroxypropanamide
-
(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanamide
-
(2R,3S,4S)-2,3,4,5-tetrahydroxypentanamide
-
(2R,4S)-6-fluoro-2',5'-dioxospiro-[chroman-4,4'-imidazoline]-2-carboxamide
-
IC50: 570 nM, mechanism, active site binding modeling, the stereochemistry of the exocyclic amide group influences the affinity for the enzyme
(2S)-2'-methoxykurarinone
-
potent inhibitor of rat lens aldose reductase
(2S)-2,3-dihydroxypropanamide
-
(2S)-3beta,7,4'-trihydroxy-5-methoxy-8-(gamma,gamma-dimethylallyl)-flavanone
(2S)-7,4'-dihydroxy-5-methoxy-8-(gamma,gamma-dimethylallyl)-flavanone
-
potent inhibitor of recombinant human aldose reductase
(2S,3R,4R)-2,3,4,5-tetrahydroxypentanamide
-
(2S,3S)-2,3,4-trihydroxybutanamide
-
(2Z)-3-(3,4-dihydroxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
-
(2Z)-3-(3-methoxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
-
(3,3-dihydroxy-1-oxo-1,3-dihydro-2H-3lambda4-naphtho[1,2-d]isothiazol-2-yl)acetic acid
i.e. NiT
(3-benzothiazol-2-yl-pyrrol-1-yl)acetic acid
-
50% inhibition at 49 nM
(3-benzyl-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
(3-methyl-1-oxo-5-phenylpyrimido[4,5-c]quinolin-2(1H)-yl)acetic acid
14fold selectivity for isoform AKR1B1 over AKR1B10
(3-sulfanyl-5H-[1,2,4]triazino[5,6-b]indol-5-yl)acetic acid
-
(3-sulfanyl[1,2,5]triazepino[4,3-b]indol-6(3H)-yl)acetic acid
-
(3-[(5-chloro-1,3-benzothiazol-2-yl)methyl]-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetic acid
thermodynamic binding data for isoform ALR2 and mutants
(3-[[(2-fluorophenyl)methyl]sulfanyl]-5H-[1,2,4]triazino[5,6-b]indol-5-yl)acetic acid
-
(3-[[2-oxo-2-(2,4,6-trimethylanilino)ethyl]sulfanyl]-5H-[1,2,4]triazino[5,6-b]indol-5-yl)acetic acid
-
(4-benzothiazol-2-yl-2-benzoylpyrrol-1-yl)acetic acid
-
50% inhibition at 45 nM
(4-benzyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)acetic acid
-
(4-hydroxy-3-methoxyphenyl)acetonitrile
-
IC50: 0.0244 mM
(4-hydroxy-3-methoxyphenyl)methamine
-
IC50: 0.0634 mM
(4-hydroxyphenyl)(6-hydroxypyrazin-2-yl)methanone
-
isolated from red ascidian Botryllus leachi, pyrazine derivative, IC50: 0.0414 mM
(4-hydroxyphenyl)[4-(4-hydroxyphenyl)-1H-imidazol-2-yl]methanone
-
isolated from red ascidian Botryllus leachi, imidazole derivative, IC50: 0.0214 mM
(4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indol-5-yl)acetic acid
-
(4S)-6-fluoro-2,3-dihydro-2'H,5'H-spiro[1-benzopyran-4,4'-imidazolidine]-2',5'-dione
-
(5-biphenyl-4-ylmethyl-2,4-dioxothiazolidin-3-yl)acetic acid
-
IC50: 0.0017 mM
(5-biphenyl-4-ylmethyl-2,4-dioxothiazolidin-3-yl)acetic acid methyl ester
-
15% inhibition of ALR2 at 0.05 mM
(5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)-acetic acid
-
IC50: 0.00026 mM
(5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)-acetic acid methyl ester
-
35% inhibition of ALR2 at 0.05 mM
(5-chloro-2-[(3-nitrobenzyl)carbamoyl]phenoxy)acetic acid
thermodynamic binding data for isoform ALR2 and mutants
(5-chloro-2-[(4-cyanobenzyl)carbamoyl]phenoxy)acetic acid
-
-
(5-methylIndoleDs)1-(3-(3,4,5-trimethoxyphenyl)-3-(5-methyl-1H-indol-3-yl)propanoyl)-4-(5-methyl-1H-indol-3-yl)piperidin-2-one
-
-
(5-methylIndoleMs)1-(3-(3,4,5-trimethoxyphenyl)-3-(5-methyl-1H-indol-3-yl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
(5-naphthalen-1-ylmethylene-2,4-dioxothiazolidin-3-yl)acetic acid
-
IC50: 0.00017 mM
(5-naphthalen-1-ylmethylene-2,4-dioxothiazolidin-3-yl)acetic acid methyl ester
-
12% inhibition of ALR2 at 0.05 mM
(5E)-5-[4-(4-oxo-4H-chromen-2-yl)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-3-chloro-4-(3,5-dibromo-4-hydroxyphenyl)-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.019 mM
(5Z)-3-chloro-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-4-(4-hydroxyphenyl)furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.0008 mM
(5Z)-4-(3,5-dibromo-4-hydroxyphenyl)-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.020 mM
(5Z)-4-(3-bromo-4-hydroxyphenyl)-3-chloro-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.013 mM
(5Z)-4-(3-bromo-4-hydroxyphenyl)-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.048 mM
(5Z)-4-(3-bromo-4-hydroxyphenyl)-5-[(3-bromo-4-hydroxyphenyl)methylidene]-3-chlorofuran-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.017 mM
(5Z)-5-(3-aminobenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.69
(5Z)-5-(3-fluorobenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 5.04
(5Z)-5-(3-hydroxybenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.97
(5Z)-5-(3-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.88
(5Z)-5-(3-methylbenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 5.03
(5Z)-5-(3-phenoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 5.21
(5Z)-5-(3-{(E)-[(4-hydroxyphenyl)imino]methyl}benzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 5.73
(5Z)-5-(4-fluorobenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 5.09
(5Z)-5-(4-hydroxy-3-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.93
(5Z)-5-(4-hydroxybenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 5.05
(5Z)-5-(4-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.39
(5Z)-5-(4-{(E)-[(4-hydroxyphenyl)imino]methyl}benzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.64
(5Z)-5-(naphthalen-1-ylmethylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.97
(5Z)-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-4-(4-hydroxyphenyl)furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.057 mM
(5Z)-5-[(3-bromo-4-hydroxyphenyl)methylidene]-3-chloro-4-(4-hydroxyphenyl)furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.046 mM
(5Z)-5-[(4-oxo-2-phenyl-4H-chromen-6-yl)methylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.89
(5Z)-5-[4-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.50
(6-amino-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazol-2-yl)acetic acid
IC50: 0.10 mM
(6-amino-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazol-2-yl)acetic acid ethyl ester
-
(6-nitro-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazol-2-yl)acetic acid
IC50: 0.180 mM
(6-nitro-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazol-2-yl)acetic acid ethyl ester
-
(6H-indolo[2,3-b]quinoxalin-6-yl)acetic acid
-
(7H-indolo[2',3':5,6][1,2,4]triazino[2,3-a]benzimidazol-7-yl)acetic acid
uncompetitive
(8-methyl-3-[[2-oxo-2-(propylamino)ethyl]sulfanyl]-5H-[1,2,4]triazino[5,6-b]indol-5-yl)acetic acid
-
(9-amino-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazol-2-yl)acetic acid
IC50: 0.10 mM
(9-amino-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazol-2-yl)acetic acid ethyl ester
-
(9-nitro-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazol-2-yl)acetic acid
IC50: 0.190 mM
(9-nitro-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazol-2-yl)acetic acid ethyl ester
-
(E)-1-(3-(1,3-diphenyl-1H-pyrazol-4-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(2,5-dimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)piperidin-2-one
-
-
(E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)pyrrolidin-2-one
-
-
(E)-1-(3-(3-(trifluoromethyl)phenyl)acryloyl)-5,6-dihydropyridin-2(1)-one
-
-
(E)-1-(3-(3-methyl-1-phenyl-1H-pyrazol-4-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(3-phenoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(4-bromophenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(4-chlorophenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(benzo[d][1,3]dioxol-5-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(furan-2-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(naphthalen-2-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(pyridin-2-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(thiophen-2-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-mesitylacryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(4-benzylpiperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(E)-1-(4-methylpiperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(E)-1-(4-phenylpiperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(E)-1-(piperidin-1-yl)-3-(3,4,5-trimethoxyphenyl) prop-2-en-1-one
-
-
(E)-1-(pyrrolidin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(E)-2-(3-(3,4,5-trimethoxyphenyl)acryloyl)benzo[d]isothiazol-3(2H)-one
-
-
(E)-2-(3-(3,4,5-trimethoxyphenyl)acryloyl)isoindolin-1-one
-
-
(E)-3-((4-chlorophenyl)(hydroxy)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-((4-fluorophenyl)(hydroxy)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(3-(3,4,5-trimethoxyphenyl)acryloyl)benzo[d]oxazol-2(3H)-one
-
-
(E)-3-(5-(3-nitrophenyl)furan-2-yl)acrylic acid
-
(E)-3-(hydroxy(2-nitrophenyl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(hydroxy(4-nitrophenyl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(hydroxy(naphthalen-2-yl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(hydroxy(p-tolyl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(hydroxy(phenyl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(hydroxy(pyridin-2-yl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(hydroxy(thiophen-2-yl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-4-(hydroxy(2-oxo-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)benzonitrile
-
-
(E)-methyl 3-(3,4,5-trimethoxyphenyl)acrylate
-
-
(E)-N-ethanethioyl-3-(3,4,5-trimethoxyphenyl)acrylamide
-
-
(E,E)-5[2-methyl-3-phenyl-2-propenylidene-4-oxo-2-thioxo-3-thiazolidine]acetic acid
(NH4)2SO4
(S)-6-fluorospiro[chroman-4,5'-imidazolidine]-2',4'-dione
(Z)-2-(5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)-N-hydroxyacetamide
-
(Z)-2-(5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)acetamide
18% inhibition at 0.0125 mM
(Z)-2-(5-naphthalen-1-ylmethylene-2,4-dioxothiazolidin-3-yl)acetamide
32% inhibition at 0.0125 mM
(Z)-2-(5-naphthalen-2-ylmethylene-2,4-dioxothiazolidin-3-yl)acetamide
3% inhibition at 0.0125 mM
(Z)-2-[2,4-dioxo-5-(3-phenoxybenzylidene)thiazolidin-3-yl]acetamide
8% inhibition at 0.0125 mM
(Z)-2-[5-(3-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide
16% inhibition at 0.0125 mM
(Z)-2-[5-(3-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide
10% inhibition at 0.0125 mM
(Z)-2-[5-(4-benzyloxybenzylidene)-2,4-dioxothiazolidin-3-yl]-N-hydroxyacetamide
-
(Z)-2-[5-(4-hydroxy-3-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide
-
(Z)-2-[5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide
31% inhibition at 0.0125 mM
(Z)-5-(naphthalen-1-ylmethylidene)-3-(3,3,3-trifluoro-2-oxopropyl)-2,4-thiazolidinedione
-
52% inhibition at 0.025 mM
(Z)-5-(naphthalen-2-ylmethylidene)-3-(3,3,3-trifluoro-2-oxopropyl)-2,4-thiazolidinedione
-
59% inhibition at 0.025 mM
(Z)-5-[(3-hydroxyphenyl)methylidene]-3-(3,3,3-trifluoro-2-oxopropyl)-2,4-thiazolidinedione
-
-
(Z)-5-[(3-methoxyphenyl)methylidene]-3-(3,3,3-trifluoro-2-oxopropyl)-2,4-thiazolidinedione
-
-
(Z)-5-[(3-phenoxyphenyl)methylidene]-3-(3,3,3-trifluoro-2-oxopropyl)-2,4-thiazolidinedione
-
64% inhibition at 0.025 mM
(Z)-5-[(4-hydroxyphenyl)methylidene]-3-(3,3,3-trifluoro-2-oxopropyl)-2,4-thiazolidinedione
-
-
(Z)-5-[(4-methoxyphenyl)methylidene]-3-(3,3,3-trifluoro-2-oxopropyl)-2,4-thiazolidinedione
-
-
(Z)-5-[(4-phenoxyphenyl)methylidene]-3-(3,3,3-trifluoro-2-oxopropyl)-2,4-thiazolidinedione
-
-
(Z)-5-[(4-phenylphenyl)methylidene]-3-(3,3,3-trifluoro-2-oxopropyl)-2,4-thiazolidinedione
-
45% inhibition at 0.025 mM
(Z)-N-hydroxy-2-(5-naphthalen-1-ylmethylene-2,4-dioxothiazolidin-3-yl)acetamide
-
(Z)-N-hydroxy-2-(5-naphthalen-2-ylmethylene-2,4-dioxothiazolidin-3-yl)acetamide
39% inhibition at 0.025 mM
(Z)-N-hydroxy-2-[2,4-dioxo-5-(3-phenoxybenzylidene)-thiazolidin-3-yl]acetamide
-
(Z)-N-hydroxy-2-[2,4-dioxo-5-(4-phenoxybenzylidene)-thiazolidin-3-yl]acetamide
-
(Z)-N-hydroxy-2-[5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide
-
([2-[(4-methoxy-1-methyl-1H-indazol-3-yl)amino]-2-oxoethyl]sulfanyl)acetic acid
HTS-03834
([5-(5-nitrofuran-2-yl)-1,3,4-oxadiazol-2-yl]sulfanyl)acetic acid
crystallization data
1'-(4-bromophenylsulfonyl)spiro[fluorene-9,5'-imidazolidine]-2',4'-dione
-
1'-(4-chlorophenylsulfonyl)spiro[fluorene-9,5'-imidazolidine]-2',4'-dione
-
1'-(4-fluorobenzene-1-sulfonyl)spiro[fluorene-9,4'-imidazolidine]-2',5'-dione
no selectivity for ALR2 over ALR1
1'-(4-methoxyphenylsulfonyl)spiro[fluorene-9,5'-imidazolidine]-2',4'-dione
-
1'-(4-methylphenylsulfonyl)spiro[fluorene-9,5'-imidazolidine]-2',4'-dione
-
1'-(4-nitrophenylsulfonyl)spiro[fluorene-9,5'-imidazolidine]-2',4'-dione
-
1'-(5-chlorothiophene-2-sulfonyl)spiro[fluorene-9,4'-imidazolidine]-2',5'-dione
3.4fold selectivity for ALR2 over ALR1
1'-(9,10-dioxo-9,10-dihydroanthracen-2-ylsulfonyl)spiro[fluorene-9,5'-imidazolidine]-2',4'-dione
-
1'-(naphthalen-2-ylsulfonyl)spiro[fluorene-9,5'-imidazolidine]-2',4'-dione
-
1,1-dioxidenaphtho[2,3-d]isothiazole-3(2H)-one
-
1,10-phenanthroline
-
-
1,2,7-trihydroxy-3,8-dimethoxy-6-methylanthracene-9,10-dione 2-O-beta-D-glucoside
-
-
1,2-benzothiazin-1,1-dioxide
-
1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid
-
1,3,7-trihydroxy-2,8-dimethoxy-6-methylanthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methylanthracene-9,10-dione
-
-
1,5-bis(3,4-dihydroxyphenyl)-1,4-pentadiene-3-one
-
IC50: 0.0034 mM
1,5-bis(3,5-di-tert-butyl-4-hydroxyphenyl)-1,4-pentadiene-3-one
-
31.0% inhibition at 0.1 mM
1,5-bis(4-hydroxy-3,5-dimethoxyphenyl)-1,4-pentadiene-3-one
-
IC50: 0.0253 mM
1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one
-
IC50: 0.0359 mM
1,5-bis(4-hydroxyphenyl)-1,4-pentadiene-3-one
-
IC50: 0.0331 mM
1-((2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)penta-2,4-dienoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-((2E,4E,6E)-7-(3,4,5-trimethoxyphenyl)hepta-2,4,6-trienoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(2-chlorobenzoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(2-iodobenzoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(1-benzyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-4-(1-benzyl-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(1-benzyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-4-(1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(1-methyl-1H-indol-3-yl)propanoyl)-4-(1-methyl-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(1-methyl-1H-indol-3-yl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(2-methyl-1H-indol-3-yl)propanoyl)-4-(2-methyl-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(2-phenyl-1H-indol-3-yl)propanoyl)-4-(2-phenyl-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(5-methoxy-1H-indol-3-yl)propanoyl)-4-(5-methoxy-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(5-nitro-1H-indol-3-yl)propanoyl)-4-(5-nitro-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(5-nitro-1H-indol-3-yl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(5-bromo-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-4-(5-bromo-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(5-bromo-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(5-fluoro-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-4-(5-fluoro-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(5-fluoro-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(5-iodo-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-4-(5-iodo-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(5-iodo-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(5-methoxy-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(4-fluorobenzoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(4-fluorophenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
2.1fold selectivity for ALR2 over ALR1
1-(4-methoxyphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
8.5fold selectivity for ALR2 over ALR1
1-(4-methylphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
1.5fold selectivity for ALR2 over ALR1
1-(4-nitrobenzoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(4-nitrobenzyl)-3-(4-(2-morpholinoethyl)piperazin-1-yl)quinoxalin-2(1H)-one
-
1-(4-nitrobenzyl)-3-(4-(4-methoxyphenyl)piperazin-1-yl)quinoxalin-2(1H)-one
-
1-(4-nitrobenzyl)-3-(4-(pyrazin-2-yl)piperazin-1-yl)quinoxalin-2(1H)-one}
-
1-(4-nitrobenzyl)-3-styryl-quinoxalin-2(1H)-one
-
1-(5-chlorothiophen-2-yl)-1,3-diazaspiro[4.5]decane-2,4-dione
1.9fold selectivity for ALR2 over ALR1
1-butyl-2-[[(4-oxo-3,4-dihydroquinazolin-2-yl)methyl]sulfanyl]-1H-benzimidazole-5-sulfonamide
classical competitive mechanism. No significant influence on 11beta-HSD activities
1-cinnamoyl-5,6-dihydropyridin-2(1H)-one
-
-
1-O-Galloyl-beta-D-glucose
1-[3-(2-phenyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl]-5,6-dihydropyridin-2(1H)-one
-
-
1-[4-benzoyl-1-(1-hydroxy-1H-pyrazol-4-yl)-1H-pyrrol-2-yl]-2,2,2-trifluoroethan-1-one
-
413fold selectivity for isoform ALR2 over ALR1
17alpha-estradiol
-
17beta-estradiol
-
2'-AMP
-
-
2,1,3-benzoxadiazol-5-yl 5-chlorothiophene-2-sulfonate
KM-07100
2,2'-dipyridyl
-
-
2,2'-[sulfonylbis(benzene-4,1-diyliminomethylylidene)]dipropanedinitrile
BTB-06667
2,2,2-trifluoro-1-[1-(1-hydroxy-1H-pyrazol-4-yl)-4-(3-methoxybenzoyl)-1H-pyrrol-2-yl]ethan-1-one
-
370fold selectivity for isoform ALR2 over ALR1
2,2,2-trifluoro-1-[1-(1-hydroxy-1H-pyrazol-4-yl)-4-(4-methoxybenzoyl)-1H-pyrrol-2-yl]ethan-1-one
-
468fold selectivity for isoform ALR2 over ALR1
2,2,2-trifluoro-1-[1-(1-hydroxy-1H-pyrazol-4-yl)-4-(4-phenoxybenzoyl)-1H-pyrrol-2-yl]ethan-1-one
-
190fold selectivity for isoform ALR2 over ALR1
2,2,2-trifluoro-1-[1-(1-hydroxy-1H-pyrazol-4-yl)-4-[4-(methanesulfonyl)benzoyl]-1H-pyrrol-2-yl]ethan-1-one
-
775fold selectivity for isoform ALR2 over ALR1
2,2,2-trifluoro-1-[1-(1-hydroxy-1H-pyrazol-4-yl)-4-[4-(methylsulfanyl)benzoyl]-1H-pyrrol-2-yl]ethan-1-one
2,2,2-trifluoro-1-[4-(3-fluorobenzoyl)-1-(1-hydroxy-1H-pyrazol-4-yl)-1H-pyrrol-2-yl]ethan-1-one
-
339fold selectivity for isoform ALR2 over ALR1
2,2,2-trifluoro-1-[4-(4-fluorobenzoyl)-1-(1-hydroxy-1H-pyrazol-4-yl)-1H-pyrrol-2-yl]ethan-1-one
2,3-dihydrospiro[4H-thiopyrano[2,3-b]pyridin-4,4'imidazolidine]-2',5'-dione
-
50% inhibition at 0.0034 mM
2,3-dihydrospiro[4H-thiopyrano[2,3-b]pyridin-4,4'imidazolidine]-2',5'-dione, sulfone derivative
-
50% inhibition at 0.0014 mM
2,5-bis(3,4-dihydroxybenzylidene)cyclopentanone
-
IC50: 0.0026 mM
2,5-bis(3,5-di-tert-butyl-4-hydroxybenzylidene)cyclopentanone
-
38.2% inhibition at 0.1 mM
2,5-bis(3-bromo-4-hydroxy-5-methoxybenzylidene)cyclopentanone
-
IC50: 0.0208 mM
2,5-bis(4-hydroxy-3,5-dimethoxybenzylidene)cyclopentanone
-
IC50: 0.0234 mM
2,5-bis(4-hydroxy-3-methoxybenzylidene)cyclopentanone
-
IC50: 0.0258 mM
2,5-bis(4-hydroxybenzylidene)cyclopentanone
-
IC50: 0.0274 mM
2,5-dihydro-3H-[1,2,4]triazino[5,6-b]indole-3-thione
-
2,5-dihydrobenzoic acid
-
-
2,6-bis(3,4-dihydroxybenzylidene)cyclohexanone
-
IC50: 0.0029 mM
2,6-bis(3,5-di-tert-butyl-4-hydroxybenzylidene)cyclohexanone
-
35.8% inhibition at 0.1 mM
2,6-bis(3-bromo-4-hydroxy-5-methoxybenzylidene)cyclohexanone
-
IC50: 0.021 mM
2,6-bis(4-hydroxy-3,5-dimethoxybenzylidene)cyclohexanone
-
IC50: 0.0249 mM
2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone
-
IC50: 0.0264 mM
2,6-bis(4-hydroxybenzylidene)cyclohexanone
-
IC50: 0.0275 mM
2,6-dichlorophenylacetic acid
-
competitive
2-(2-oxo-3-((3,4,5-trifluorophenyl)amino)quinoxalin-1(2H)-yl)acetic acid
-
-
2-(2-oxo-3-phenethylquinoxalin-1(2H)-yl)acetic acid
22% inhibition
2-(2-oxo-3-styrylquinoxalin-1(2H)-yl)acetic acid
32% inhibition
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one
-
2-(3,4-dihydroxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one
-
2-(3,4-dihydroxyphenyl)-6-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one
-
2-(3,4-dihydroxyphenyl)-9-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one
-
2-(3,4-dimethoxyphenyl)-6-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one
-
2-(3,4-dimethoxyphenyl)-ethanoic acid
-
IC50: 0.0303 mM
2-(3,7-bis(4-fluorophenyl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(3-((2,4-difluorophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-((4-bromo-2-fluorophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
-
2-(3-((4-bromophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-((4-fluorophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-(2,4-difluorophenylamino)-6-nitro-2-oxoquinoxalin-1(2H)-yl) acetic acid}
41% inhibition
2-(3-(2,4-dihydroxyphenyl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(3-(3-(tert-butylamino)-3-oxoprop-1-en-1-yl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
25% inhibition
2-(3-(3-indolyl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(3-(4-(4-methoxyphenyl) piperazin-1-yl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
48% inhibition
2-(3-(4-bromo-2-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-(4-bromo-2-fluorophenoxy)-6-chloro-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-(4-bromo-2-fluorophenoxy)-6-fluoro-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-(4-bromo-2-fluorophenoxy)-7-chloro-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-(4-bromo-2-fluorophenoxy)-7-fluoro-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-(4-bromophenoxy)-6-chloro-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-(4-bromophenoxy)-6-fluoro-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-(4-bromophenoxy)-7-chloro-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-(4-bromophenoxy)-7-fluoro-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-(4-bromothiophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(3-(4-chlorothiophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(3-(4-fluorophenethyl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
40% inhibition
2-(3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(3-(4-fluorophenyl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(3-(4-fluorostyryl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
47% inhibition
2-(3-(4-fluorostyryl)-6-nitro-2-oxoquinoxalin-1(2H)-yl)acetic acid}
25% inhibition
2-(3-(4-hydroxyphenyl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(3-benzoyl-1H-pyrrol-1-yl)acetic acid
-
-
2-(3-phenoxy-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(3-phenyl-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(3-thiophenoxy-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(4-((E)-4-oxo-5-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((E)-4-oxo-5-((1-phenyl-3-m-tolyl-1H-pyrazol-4-yl)methylene)-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((E)-4-oxo-5-((1-phenyl-3-p-tolyl-1H-pyrazol-4-yl)methylene)-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((E)-5-((3-(3-bromophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((E)-5-((3-(3-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((E)-5-((3-(3-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((E)-5-((3-(3-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl) benzamido)acetic acid
-
-
2-(4-((E)-5-((3-(3-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((E)-5-((3-(4-bromophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl) benzamido) acetic acid
-
-
2-(4-((E)-5-((3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((E)-5-((3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((E)-5-((3-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl) benzamido)acetic acid
-
-
2-(4-((E)-5-((3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(2,3-dichlorobenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido) acetic acid
-
-
2-(4-((Z)-5-(2-bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(2-chlorobenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido)aceticacid
-
-
2-(4-((Z)-5-(2-fluorobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(2-methoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(2-methylbenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(2-nitrobenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(3,4,5-trimethoxybenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido) acetic acid
-
-
2-(4-((Z)-5-(3-bromobenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(3-chlorobenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(3-fluorobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(3-methoxybenzylidene)-4-oxo-2-thioxothiazolidin-3yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(3-methylbenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(3-nitrobenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(4-bromobenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(4-chlorobenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(4-fluorobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(4-formylbenzylidene) 4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(4-methoxybenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(4-methylbenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-(4-nitrobenzylidene)4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-((Z)-5-benzylidene-4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
-
2-(4-(4-oxo-2-thioxothiazolidin-3-yl)benzamido)acetic acid
-
i.e. rhodanine-3-hippuric acid
2-(4-hydroxy-3-methoxyphenyl)-7-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
-
2-(4-hydroxy-3-methoxyphenyl)ethanoic acid
-
derived from ginger rhizom, Zingiber officinale, IC50: 0.0185 mM, suppresses nt only sorbitol accumulation in human erythrocytes
2-(4-hydroxy-3-methoxyphenyl)ethanol
-
derived from ginger rhizom, Zingiber officinale, IC50: 0.0192 mM, suppresses sorbitol accumulation in human erythrocytes
2-(6-bromo-3-(2,4-dihydroxyphenyl)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(6-bromo-3-(4-bromo-2-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(6-bromo-3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(6-bromo-3-(4-bromothiophenoxy)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(6-bromo-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(6-chloro-3-(2,4-dihydroxyphenyl)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(6-chloro-3-(4-fluoro-styryl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
25% inhibition
2-(6-chloro-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(6-fluoro-3-(2,4-dihydroxyphenyl)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(6-fluoro-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(6-nitro-1,1,3-trioxo-1,3-dihydro-2H-1lambda~6~,2-benzothiazol-2-yl)propanoic acid
-
2-(7-(4-fluorobenzyl)-3-(2,4-dihydroxyphenyl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(7-bromo-3-(2,4-dihydroxyphenyl)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(7-bromo-3-(3-indolyl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(7-bromo-3-(4-bromo-2-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(7-bromo-3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(7-bromo-3-(4-bromothiophenoxy)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(7-bromo-3-(4-chlorothiophenoxy)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(7-bromo-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(7-chloro-2-oxo-3-styrylquinoxalin-1(2H)-yl) acetic acid}
35% inhibition
2-(7-chloro-3-(2,4-dihydroxyphenyl)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(7-chloro-3-(2-benzothiophene)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(7-chloro-3-(4-bromothiophenoxy)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(7-chloro-3-(4-chlorothiophenoxy)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(7-chloro-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(7-chloro-3-(4-fluorophenyl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(7-fluoro-3-(2,4-dihydroxyphenyl)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(7-fluoro-3-(4-bromothiophenoxy)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(7-fluoro-3-(4-chlorothiophenoxy)-2-oxoquinoxalin-1(2H)-yl)-acetic acid
-
2-(7-fluoro-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
-
2-(7-fluoro-3-(4-fluorophenyl)-2-oxoquinoxalin-1(2H)-yl)acetic acid
-
2-(carboxymethyl)-1-oxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid 3,3-dioxide
crystallization data
2-amino-4-oxo-3,4-dihydropteridine-6-carboxylic acid
-
2-amino-4-oxo-3,4-dihydropteridine-7-carboxylic acid
-
2-benzyl-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid
IC50: 0.068 mM; IC50: 0.10 mM
2-benzyl-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid methyl ester
-
2-benzyl-1,3,3-trioxo-2,3-dihydro-1H-3lambda~6~-naphtho[1,2-d][1,2]thiazole-4-carboxylic acid
-
2-bromophenylacetic acid
-
competitive
2-carboxymethyl-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid
IC50: 140 nM, binding structure analysis
2-carboxymethyl-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid carboxymethyl ester
IC50: 550 nM, binding structure analysis
2-Chlorophenylacetic acid
-
competitive
2-ethoxycarbonyl-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid ethoxycarbonylmethyl ester
-
2-hydroxyphenylacetic acid
-
competitive
2-isopropoxycarbonylmethyl-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid isopropyl ester
-
2-mercaptoethanol
-
-
2-methyl-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid
IC50: 0.088 mM
2-methyl-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid ethoxycarbonyl methylester
-
2-methyl-1,3,3-trioxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid methyl ester
-
2-naphthylacetic acid
-
competitive
2-oxo-3-(3,4,5-trihydroxyphenoxy)-1,8-naphthyridine-1(2H)-carboxylic acid
21.7fold selectivity for AKR1B1 over AKR1A1
2-oxo-3-(3,4,5-trimethoxyphenoxy)-1,8-naphthyridine-1(2H)-carboxylic acid
20.8fold selectivity for AKR1B1 over AKR1A1
2-oxo-3-phenoxy-1,8-naphthyridine-1(2H)-carboxylic acid
27fold selectivity for AKR1B1 over AKR1A1
2-Oxodecanoate
-
-
2-oxoglutarate
-
-
2-Oxoheptanoate
-
-
2-Oxohexanoate
-
-
2-Oxoisohexanoate
-
-
2-oxoisopentanoate
-
-
2-oxononanoate
-
-
2-oxooctanoate
-
-
2-oxopentanoate
-
-
2-phenyl-4H-pyrido[1,2-a]pyrimidin-4-one
-
2-tert-butylsulfonylnaphthalene-1,3-dicarboxylic acid
-
2-tert-butylsulfonylnaphthalene-1-carboxylic acid
-
2-[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino]-4-phenylbutanoic acid
-
2-[(3,4-dihydroxyphenyl)methyl]-6-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one
-
2-[(4-fluorobenzyl)[(2-fluorophenyl)sulfonyl]amino]-N-[2-(3-fluorophenyl)ethyl]acetamide
-
2-[2-(carboxymethoxy)-2-oxoethyl]-1-oxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid 3,3-dioxide
crystallization data
2-[5-fluoro-2-methyl-1-p-(methylsulphinyl)benzylidine]indene-3-acetic acid
-
non-competitive
2-[[5-(carboxymethyl)-3-oxo-3,5-dihydro-2H-[1,2,4]triazino[5,6-b]indol-2-yl]methyl]benzoic acid
-
424fold selectivity for ALR2 over ALR1
3',3'',5',5''-tetrabromophenolphthalein
-
less than 25% inhibition at 0.1 mM
3'-(4-bromophenylsulfonyl)spiro[fluorene-9,5'-imidazolidine]-2',4'-dione
-
3'-(4-chlorophenylsulfonyl)spiro[fluorene-9,5'-imidazolidine]-2',4'-dione
-
3'-(4-fluorobenzene-1-sulfonyl)spiro[fluorene-9,4'-imidazolidine]-2',5'-dione
10fold selectivity for ALR2 over ALR1
3'-(4-methoxyphenylsulfonyl)spiro[fluorene-9,5'-imidazolidine]-2',4'-dione
-
3'-(4-methylphenylsulfonyl)spiro[fluorene-9,50-imidazolidine]-2',4'-dione
-
3'-(4-nitrophenylsulfonyl)spiro[fluorene-9,5'-imidazolidine]-2',4'-dione
-
3'-(5-chlorothiophene-2-sulfonyl)spiro[fluorene-9,4'-imidazolidine]-2',5'-dione
1.1fold selectivity for ALR2 over ALR1
3'-(9,10-dioxo-9,10-dihydroanthracen-2-ylsulfonyl)spiro[fluorene-9,5'-imidazolidine]-2',4'-dione
-
3'-(naphthalen-2-ylsulfonyl)spiro[fluorene-9,5'-imidazolidine]-2',4'-dione
-
3'-AMP
-
-
3,3-dioxidenaphtho[1,2-d]isothiazole-1(2H)-one
-
3,3-Tetramethylene glutaric acid
-
-
3,3-Tetramethyleneglutaric acid
-
-
3,4-dihydroxyphenylacetic acid
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
3,4-dinitro-2,5-bis(phenylsulfanyl)thiophene
SEW-05367
3,5-bis(3,4-dihydroxybenzylidene)-4-piperidone
-
IC50: 0.0049 mM
3,5-bis(3,5-di-tert-butyl-4-hydroxybenzylidene)-4-piperidone
-
29.2% inhibition at 0.1 mM
3,5-bis(3-bromo-4-hydroxy-5-methoxybenzylidene)-4-piperidone
-
IC50: 0.0208 mM
3,5-bis(4-hydroxy-3,5-dimethoxybenzylidene)-4-piperidone
-
IC50: 0.0223 mM
3,5-bis(4-hydroxy-3-methoxybenzylidene)-4-piperidone
-
IC50: 0.0299 mM
3,5-bis(4-hydroxyphenyl)-4-piperidone
-
IC50: 0.0311 mM
3,5-dichlorosalicylic acid
uncompetitive inhibition
3,6,7-trichloroquinoxalin-2(1H)-one
-
-
3,6-dichloroquinoxalin-2(1H)-one
-
-
3,7-dichloroquinoxalin-2(1H)-one
-
-
3-(1H-indol-1-yl)propanoic acid
-
3-(2,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-6-(3-methylbut-2-en-1-yl)-4H-chromen-4-one
3-(2-phenylthiazole-4-yl)propanoic acid
-
3-(3,4,5-trimethoxyphenyl)-3-(2-methyl-1H-indol-3-yl)propanoic acid
-
-
3-(3,4-dihydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
16.9fold selectivity for AKR1B1 over AKR1A1
3-(3,4-dimethoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
17.6fold selectivity for AKR1B1 over AKR1A1
3-(3,5-dihydroxy-4-methoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
25.8fold selectivity for AKR1B1 over AKR1A1
3-(3,5-dihydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
20.8fold selectivity for AKR1B1 over AKR1A1
3-(3,5-dimethoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
21.5fold selectivity for AKR1B1 over AKR1A1
3-(3-benzoyl-1H-pyrrol-1-yl)propanoic acid
-
-
3-(3-hydroxy-4,5-dimethoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
31.6fold selectivity for AKR1B1 over AKR1A1
3-(3-hydroxy-4-methoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
19.3fold selectivity for AKR1B1 over AKR1A1
3-(3-hydroxy-5-methoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
15.1fold selectivity for AKR1B1 over AKR1A1
3-(4-fluorophenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
2.3fold selectivity for ALR2 over ALR1
3-(4-fluorostyryl)-1-(4-nitrobenzyl)quinoxalin-2(1H)-one
-
3-(4-hydroxy-3-methoxyphenyl)propanol
-
IC50: 0.283 mM
3-(4-hydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
15.9fold selectivity for AKR1B1 over AKR1A1
3-(4-methoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
20fold selectivity for AKR1B1 over AKR1A1
3-(4-methoxyphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
1.2fold selectivity for ALR2 over ALR1
3-(4-methylphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
11fold selectivity for ALR2 over ALR1
3-(4-nitro-1,1,3-trioxo-1,3-dihydro-2H-1lambda~6~,2-benzothiazol-2-yl)propanoic acid
-
3-(4-nitrophenyl)-2-[(phenylsulfonyl)amino]propanoic acid
SPB-08302
3-(5-(3-(trifluormethyl)phenyl)thiophene-2-yl)propanoic acid
-
3-(5-(3-acetylphenyl)furan-2-yl)propanoic acid
-
3-(5-(3-aminophenyl)furan-2-yl)propanoic acid
-
3-(5-(3-methoxyphenyl)furan-2-yl)propanoic acid
-
3-(5-(3-methoxyphenyl)thiophene-2-yl)propanoic acid
-
3-(5-(3-methylphenyl)furan-2-yl)propanoic acid
-
3-(5-(3-methylphenyl)thiophene-2-yl)propanoic acid
-
3-(5-(3-methylsulfonyl)phenylfuran-2-yl)propanoic acid
-
3-(5-(3-nitrophenyl)furan-2-yl)propanoic acid
-
3-(5-(3-nitrophenyl)thiophene-2-yl)propanoic acid
-
3-(5-(3-trifluormethyl)phenylfuran-2-yl)propanoic acid
-
3-(5-chlorothiophen-2-yl)-1,3-diazaspiro[4.5]decane-2,4-dione
127fold selectivity for ALR2 over ALR1, 79% reduction in blood glucose level
3-(5-phenylfuran-2-yl)propanoic acid
-
3-(5-phenylthiophene-2-yl)propanoic acid
-
3-(5-pyridine-2-yl-furan-2-yl)propanoic acid
-
3-(5-pyridine-3-yl-furan-2-yl)propanoic acid
-
3-(6-acetamido-1,1,3-trioxo-1,3-dihydro-2H-1lambda~6~,2-benzothiazol-2-yl)propanoic acid
-
3-(benzo[b] thiophen-3-yl)-1-(4-nitrobenzylquinoxalin-2(1H)-one
-
3-benzyl-1-methyl-2-oxo-1,2-dihydroquinolin-4-yl 4-methylbenzenesulfonate
NRB-05245
3-chloro-6-fluoroquinoxalin-2(1H)-one
-
-
3-chloro-6-methylquinoxalin-2(1H)-one
-
-
3-chloro-6-nitroquinoxalin-2(1H)-one
-
-
3-chloro-7-fluoroquinoxalin-2(1H)-one
-
-
3-chloro-7-methoxyquinoxalin-2(1H)-one
-
-
3-chloro-7-methylquinoxalin-2(1H)-one
-
-
3-chloroquinoxalin-2(1H)-one
-
-
3-hydroxy-4-methoxymandelic acid
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
3-hydroxybutyrate
3-hydroxybutyric acid
-
-
3-hydroxycoumarin
-
-
3-morpholino syndnonimine
-
1 mM, 76% inhibition, reversed by incubation with fresh media
3-nitro-L-tyrosine
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
3-O-caffeoylquinic acid
-
-
3-tert-butylsulfonylnaphthalene-2-carboxylic acid
-
3-[(4-bromo-2-fluorophenyl)methyl]-3,4-dihydro-4-oxo-1-phthalazineacetic acid
-
recombinant from baculovirus system in Spodoptera frugiperda cells
3-[2-(carboxymethoxy)-4-fluorobenzamido]benzoic acid
the ligand directs its acid group toward the surrounding solvent and accommodates the hydrophobic cleft adjacent to the sealed specificity pocket
3-[3,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-6-(3-methylbut-2-en-1-yl)-4H-chromen-4-one
3-[3-[(diethylamino)methyl]-1H-indol-1-yl]propanoic acid
-
3-[6-(3-methylbutanamido)-1,1,3-trioxo-1,3-dihydro-2H-1lambda~6~,2-benzothiazol-2-yl]propanoic acid
-
30-norhederagenin
-
-
4-(3-benzoyl-1H-pyrrol-1-yl)butanoic acid
-
-
4-(4-hydroxy-3-methoxyphenyl)-2-butanone
-
IC50: 0.197 mM
4-(4-hydroxy-3-methoxyphenyl)butanol
-
IC50: 0.642 mM
4-(5-(3-methylphenyl)thiophene-2-yl)butanoic acid
-
4-(5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)-2-butenoic acid
-
21% inhibition of ALR2 at 0.05 mM
4-(5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)-2-butenoic acid methyl ester
-
6% inhibition of ALR2 at 0.05 mM
4-(5-phenylthiophene-2-yl)butanoic acid
-
4-amino-N-(3,5-difluoro-4-hydroxyphenyl)benzenesulfonamide
-
-
4-androsten-17alpha-ol-3-one
i.e. epitestosterone
4-androsten-17beta-ol-3-one
i.e. testosterone
4-androstene-3,17-dione
-
4-hydroxy-3-methoxymandelic acid
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
4-hydroxy-3-methoxyphenol
-
IC50: 0.273 mM
4-hydroxy-3-methoxyphenyl methanol
-
IC50: 0.0244 mM
4-hydroxy-3-methoxyphenylacetic acid
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
4-hydroxy-3-methoxyphenyllactic acid
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
4-hydroxy-trans-2-nonenal
4-hydroxybenzoic acid
-
-
4-Hydroxycoumarin
-
-
4-O-butylpaeoniflorin
-
-
4-oxo-4-(5-(3-methylphenyl)thiophene-2-yl)butanoic acid
-
4-oxo-4-(5-phenylthiophen-2-yl)butanoic acid
-
4-pregenene-21-ol-3,20-dione
i.e. 11-deoxycorticosterone
4-pregnene-11beta,17alpha,21-triol-3,20-dione
i.e. cortisol
4-pregnene-11beta,21-diol-3,20-dione
i.e. corticosterone
4-pregnene-17alpha,21-diol-3,11,20-trione
i.e. cortisone
4-pregnene-18-al-11beta,21-diol-3,20-dione
i.e. aldosteron
4-[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino]butanoic acid
-
4-[(3-nitrophenyl)methyl]-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylic acid
-
4-[2,4-dioxo-5-(3-phenoxybenzylidene)thiazolidin-3-yl]-2-butenoic acid
-
19% inhibition of ALR2 at 0.05 mM
4-[2,4-dioxo-5-(3-phenoxybenzylidene)thiazolidin-3-yl]-2-butenoic acid methyl ester
-
25% inhibition of ALR2 at 0.05 mM
4-[2,4-dioxo-5-(4-phenoxybenzylidene)thiazolidin-3-yl]-2-butenoic acid
-
57% inhibition of ALR2 at 0.05 mM
4-[3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid
crystallization data
4-[3-(5-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidin-6-yl)-1,2,4-oxadiazol-5-yl]butanoic acid
SB-02066; SEW-01456
4-[5,7-dimethoxy-6-(3-methylbut-2-en-1-yl)-2H-chromen-3-yl]benzene-1,3-diol
4-[5-(4-benzyloxybenzylidene)-2,4-dioxothiazolidin-3-yl]-2-butenoic acid methyl ester
-
23% inhibition of ALR2 at 0.05 mM
4-[5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]-2-butenoic acid
-
IC50: 0.0042 mM
4-[7-hydroxy-5-methoxy-6-(3-methylbut-2-en-1-yl)-2H-chromen-3-yl]benzene-1,3-diol
5'-AMP
-
-
5,5-diphenylhydantoin
5,6-dihydro-1-((E)-3-(3,4,5-trimethoxyphenyl)acryloyl)pyridin-2(1H)-one
-
-
5-(3-aminobenzylidene)-2,4-thiazolidinedione
-
IC50: 0.0202 mM
5-(3-hydroxybenzylidene)-2,4-thiazolidinedione
-
IC50: 0.0107 mM
5-(3-methoxybenzyl)-2,4-thiazolidinedione
-
16% inhibition of ALR2 at 0.05 mM
5-(3-nitrobenzylidene)-2,4-thiazolidinedione
-
21% inhibition of ALR2 at 0.05 mM
5-(3-phenoxybenzyl)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.10
5-(3-phenoxybenzyl)-2,4-thiazolidinedione
-
IC50: 0.0789 mM
5-(4-aminobenzylidene)-2,4-thiazolidinedione
-
44% inhibition of ALR2 at 0.05 mM
5-(4-benzyloxybenzyl)-2,4-thiazolidinedione
-
IC50: 0.0314 mM
5-(4-benzyloxybenzylidene)-2,4-thiazolidinedione
-
10% inhibition of ALR2 at 0.05 mM
5-(4-hydroxybenzylidene)-2,4-thiazolidinedione
-
IC50: 0.009 mM
5-(4-methoxybenzyl)-2,4-thiazolidinedione
-
21% inhibition of ALR2 at 0.05 mM
5-(4-nitrobenzylidene)-2,4-thiazolidinedione
-
37% inhibition of ALR2 at 0.05 mM
5-(4-phenoxybenzyl)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.39
5-(4-phenoxybenzyl)-2,4-thiazolidinedione
-
IC50: 0.0404 mM
5-(biphenyl-4-ylmethyl)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.18
5-androsten-3beta-ol-17-one
i.e. dehydroepiandrosterone
5-biphenyl-4-ylmethyl-2,4-thiazolidinedione
-
IC50: 0.0658 mM
5-biphenyl-4-ylmethylene-2,4-thiazolidinedione
-
20% inhibition of ALR2 at 0.05 mM
5-cholenic acid-3beta-ol
-
5-hydroxy-3S-hydroxymethyl-6-methyl-2,3-dihydrobenzofuran
-
-
5-naphthalen-1-ylmethylene-2,4-thiazolidinedione
-
IC50: 0.0107 mM
5-oxo-3-phenyl-5-(quinolin-2-ylamino)pentanoic acid
HTS-06058
5-[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino]pentanoic acid
-
5-[(4-oxo-2-phenyl-4H-chromen-6-yl)methyl]-1,3-thiazolidine-2,4-dione
-
-
5-[(6-isopropyl-4-oxo-4H-chromen-3-yl)methylene]thiazolidine-2,4-dione
-
-
5-[(6-methyl-4-oxo-4H-chromen-3-yl)methylene]thiazolidine-2,4-dione
-
-
5-[3-(4-oxo-4H-chromen-2-yl)benzyl]-1,3-thiazolidine-2,4-dione
-
-
5-[4-(4-oxo-4H-chromen-2-yl)benzyl]-1,3-thiazolidine-2,4-dione
-
-
5-[4-(benzyloxy)benzyl]-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.50
5alpha-Androstan-17alpha-ol-3-one
-
5alpha-androstan-17beta-ol-3-one
i.e. 5alpha-dehydrotestosterone
5alpha-Androstan-3alpha-ol-17-one
-
5alpha-Androstan-3beta-ol-17-one
competitive inhibition with respect to geraniol
5alpha-androstane-3,17-dione
competitive inhibition with respect to geraniol
5alpha-androstane-3alpha,17beta-diol
-
5alpha-Androstane-3beta,17beta-diol
-
5alpha-cholanic acid-3beta-ol
-
5alpha-pregnan-3beta-ol-20-one
-
5alpha-pregnane-21-ol-3,20-dione
-
5alpha-pregnane-3,20-dione
competitive inhibition with respect to geraniol
5beta-androstan-17beta-ol-3-one
-
5beta-Androstan-3alpha-ol-17-one
-
5beta-androstan-3beta-ol-17-one
-
5beta-androstane-3,17-dione
-
5beta-androstane-3beta,17beta-diol
-
5beta-cholan-24-ol
-
5beta-cholanic acid
competitive inhibition with respect to geraniol
5beta-cholanic acid methyl ester
-
5beta-cholanic acid-3-one
-
5beta-cholanic acid-3alpha,12alpha-diol
i.e. chenodeoxycholic acid
5beta-cholanic acid-3alpha,6alpha-diol
i.e. hyodeoxycholic acid
5beta-cholanic acid-3alpha,7alpha,12alpha-triol
i.e. cholic acid
5beta-cholanic acid-3alpha,7alpha-diol
i.e. deoxycholic acid
5beta-cholanic acid-3alpha,7beta-diol
i.e. ursodeoxycholic acid
5beta-cholanic acid-3alpha-ol
i.e. lithocholic acid
5beta-cholanic acid-3beta-ol
i.e. isolithocholic acid
5beta-Pregnan-3alpha-ol-20-one
-
5beta-Pregnan-3beta-ol-20-one
-
5beta-pregnane-3,20-dione
-
6',6''-dinitrorosmarinic acid
docking structure with ALR2, overview
6'-nitrorosmarinic acid
docking structure with ALR2, overview
6,7-dichloro-3-(4-methylpiperazin-1-yl)quinoxalin-2(1H)-one
-
-
6,7-dihydroxy-4-methylcoumarin
-
-
6,7-dihydroxy-4-phenylcoumarin
-
binds to ALR2 in a different manner from epalrestat, molecular docking, overview. Suppresses galactitol accumulation
6,7-dihydroxycoumarin
-
-
6-(2,3-dichlorobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 55 nM
6-(2,3-dichlorophenylmethanesulfonyl)-2H-pyridazin-3-one
-
IC50: 35 nM
6-(2,3-difluorobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 390 nM
6-(2,3-difluorophenylmethanesulfonyl)-2H-pyridazin-3-one
-
IC50: 257 nM
6-(2,4-dichlorobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 190 nM
6-(2,4-dichlorophenylsulfonyl)-2H-pyridazin-3-one
-
-
6-(2,4-difluorobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 870 nM
6-(2,5-dichlorobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 73 nM
6-(2,6-dichlorobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 50 nM
6-(2,6-dichlorophenylmethanesulfonyl)-2H-pyridazin-3-one
-
IC50: 52 nM
6-(2-bromobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 210 nM
6-(2-chloro-4-fluorobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 280 nM
6-(2-chloro-6-fluorophenylmethanesulfonyl)-2H-pyridazin-3-one
-
IC50: 26 nM
6-(2-chlorobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 170 nM
6-(2-chlorophenylmethanesulfonyl)-2H-pyridazin-3-one
-
IC50: 118 nM
6-(2-fluoro-3-chlorophenylmethanesulfonyl)-2H-pyridazin-3-one
-
IC50: 54 nM
6-(2-fluoro-3-trifluoromethylphenylmethanesulfonyl)-2H-pyridazin-3-one
-
IC50: 44 nM
6-(2-fluoro-4-bromophenylmethanesulfonyl)-2H-pyridazin-3-one
-
IC50: 667 nM
6-(2-fluorobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 540 nM
6-(2-fluorophenylmethanesulfonyl)-2H-pyridazin-3-one
-
IC50: 422 nM
6-(2-trifluoromethylphenylmethanesulfonyl)-2H-pyridazin-3-one
-
IC50: 500 nM
6-(3,4-dichlorobenzenesulfonyl)-2H-pyridazin-3-one
-
-
6-(3,5-dichlorobenzenesulfonyl)-2H-pyridazin-3-one
-
-
6-(3,5-dimethylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 13 nM
6-(3-chlorobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 240 nM
6-(3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 140 nM
6-(3-phenylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 23 nM
6-(3-trifluoromethylbenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 175 nM
6-(3-trifluoromethylphenylmethanesulfonyl)-2H-pyridazin-3-one
-
IC50: 72 nM
6-(3-[4-fluorophenyl]benzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 49 nM
6-(4-bromo-2-fluorobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 140 nM
6-(4-bromobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 350 nM
6-(4-chlorobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 380 nM
6-(4-fluorobenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 474 nM
6-(4-methoxybenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 0.002 mM
6-(4-trifluoromethylbenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 360 nM
6-(5,6-methylenedioxyindole-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 0.0038 mM
6-(5,7-dichlorobenzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 87 nM
6-(5,7-dichloroindole-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 200 nM
6-(5-chloro,3-methylbenzofuran-2-sulfonyl)2H-pyridazin-3-one
-
6-(5-chloro-3-ethylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 6 nM
6-(5-chloro-3-isopropylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 92 nM
6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 0.001 mM
6-(5-chloro-3-methylbenzothiophene-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 55 nM
6-(5-chloro-3-phenylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 34 nM
6-(5-chlorobenzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 25 nM
6-(5-chloroindole-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 0.0011 mM
6-(5-fluoro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 3 nM
6-(5-methoxybenzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 230 nM
6-(5-methylbenzothiophene-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 160 nM
6-(5-trifluoromethyl-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 5 nM
6-(6-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 190 nM
6-(6-chloroindole-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 645 nM
6-(6-fluoroindole-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 0.0014 mM
6-(7-chloroindole-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 450 nM
6-(alpha-naphthylmethylbenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 150 nM
6-(benzofuran-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 150 nM
6-(benzothiazole-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 450 nM
6-(benzothiophene-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 180 nM
6-(beta-naphthylmethylbenzenesulfonyl)-2H-pyridazin-3-one
-
IC50: 360 nM
6-(biphenyl-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 0.0022 mM
6-(indole-2-sulfonyl)-2H-pyridazin-3-one
-
IC50: 590 nM
6-bromo-3-(3,5-dihydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
19.8fold selectivity for AKR1B1 over AKR1A1
6-bromo-3-chloroquinoxalin-2(1H)-one
-
-
6-chloro-3-(3,5-dihydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
18.4fold selectivity for AKR1B1 over AKR1A1
6-hydroxy-2-phenyl-4H-pyrido[1,2-a]pyrimidin-4-one
-
6-hydroxy-7-methoxycoumarin
-
-
6-hydroxycoumarin
-
-
6-methoxypaeoniflorigenone
-
-
6-[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino]hexanoic acid
-
6-[(5-chloro-3-methyl-1-benzofuran-2-yl)sulfonyl]pyridazin-3(2H)-one
binding structure, inhibition mechanism, residues Trp111, His110, Thr113, Tyr48, Trp20, and Phe122, and the residues of the C-terminal loop Ala299, Leu300, Leu301, Ser302, Cys303 are involved, overview
6-[[(di(2,4-dimethoxyphenyl)methylidene)amino]oxy]hexanoic acid
-
-
6-[[(di(3,5-dimethoxyphenyl)methylidene)amino]oxy]hexanoic acid
-
-
6-[[(di(4-methoxy-3-methylphenyl)methylidene)amino]oxy]hexanoic acid
-
-
7-bromo-3-chloroquinoxalin-2(1H)-one
-
-
7-hydroxy-4-methylcoumarin
-
-
7-Hydroxy-4-oxo-4H-chromen-2-carboxylic acid
-
-
7-hydroxy-4-phenylcoumarin
-
-
7-hydroxy-6-methoxycoumarin
-
-
7-hydroxycoumarin
-
-
7-hydroxylcoumarin-4-acetic acid
-
-
7-hydroxylcoumarinyl-4-acetic acid
-
-
7-methoxycoumarin
-
-
7-methyl-2,3-dihydrospiro[4H-thiopyrano[2,3-b]pyridin-4,4'imidazolidine]-2',5'-dione
-
50% inhibition at 0.0011 mM
8-bromo-4,4a-5,6-tetrahydrothieno[2,3-h]cinnolinone-N2-alkanoic acid
-
4fold decreased inhibitory potency compared to the nonsubstituted parent compound
8-chloro-4,4a-5,6-tetrahydrothieno[2,3-h]cinnolinone-N2-alkanoic acid
-
4fold decreased inhibitory potency compared to the nonsubstituted parent compound
8-lavandulylkaempferol
8-methoxy-N-[(1S)-2-methyl-1-(5-phenyl-1H-imidazol-2-yl)propyl]-2H-1-benzopyran-3-carboxamide
-
8-methoxy-N-[(5-phenyl-1H-imidazol-2-yl)methyl]-2H-1-benzopyran-3-carboxamide
-
8-methoxy-N-[[5-(4-methoxyphenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
-
8-methyl-4,4a-5,6-tetrahydrothieno[2,3-h]cinnolinone-N2-alkanoic acid
-
2fold decreased inhibitory potency compared to the nonsubstituted parent compound
8-O-benzoylpaeonidanin
-
-
8-phenylsulfonylphthalazin-2H-3-one
-
IC50: 55 nM
acetoacetate
-
-
alpha-benzoyloxypaeoniflorin
-
-
Alrestatin
ammonium acetate
-
-
apiopaeonoside
-
-
Barbital
benzbromarone
-
-
benzoylpaeoniflorin
-
-
berberine chloride
-
50% inhibition at 13.98 nM
berberine iodide
-
50% inhibition at 32.84 nM
berberine sulfate
-
50% inhibition at 13.45 nM
beta-benzoyloxypaeoniflorin
-
-
bezafibrate
-
noncompetitive, IC50: 0.003 mM, recombinant enzyme
bisdemethoxycurcumin
-
i.e. 1,7-bis(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione, extracted from Curcuma longa roots, IC50: 0.0137 mM
butein
-
89.9% inhibition at 0.002 mM
c-3',5'-AMP
-
-
Ca2+
-
10 mM inhibits complex formation of ALR 2 with alpha-crystallin
capsaicin
-
noncompetitive
chlorogenic acid
-
-
Cibacron blue F3GA
competitive inhibition with respect to NADP+, noncompetitive inhibition with respect to geraniol
ciprofibrate
-
competitive, IC50: 0.00086 mM, recombinant enzyme
citrate
-
inhibition is pH-dependent
Clofibric acid
-
noncompetitive, IC50: 0.0012 mM, recombinant enzyme
coptisine
coumarin
-
-
CuCl2
curcumin
D-mannitol
-
-
daidzein
-
-
davallialactone
delphinidin 3-O-beta-galactopyranoside
-
most potent inhibitor
delphinidin 3-O-beta-galactopyranoside-3',5'-di-O-beta-glucopyranoside
-
-
demethoxycurcumin
-
i.e. 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione, extracted from Curcuma longa roots, IC50: 0.0159 mM
desmethylanhydroicaritin
diadzin
-
-
Diphenic acid
-
less than 25% inhibition at 0.5 mM
disodium 4,6-dioxo-10-propyl-4H,6H-pyranol[3,2-g-]-quinoline-2,8-dicarboxylate
-
non-competitive
dithiothreitol
DL-dihydrolipoic acid
-
binds very tight to the enzyme, best inhibitor of the investigated, competitive
DL-lipoamide
-
binds three-fold more weakly than D,L-lipoic acid, competitive
DL-lipoic acid
-
is effective in the treatment of diabetic complications, binds tightly to the enzyme, competitive
DTT
-
activates the enzyme in healthy heart slightly, but slightly inhibits the ischemic heart enzyme
ellagic acid
epalrestat
epiberberine
estriol
i.e. 16alpha-hydroxyestradiol
Ethosuccinimide
-
-
ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate
-
an AR inhibitor, abolishes the accumulation of TPA-treated cells in S phase was almost completely
Euphorbia regis-jubae aqueous extract
-
-
-
Euphorbia regis-jubae hydroethanolic extract
-
-
-
fenofibrate
-
competitive, IC50: 0.00056 mM, recombinant enzyme
ferulic acid
-
-
fidarestat
fisetin
-
31.1% inhibition at 0.002 mM
folic acid
-
formononetin
-
-
fustin
-
20.1% inhibition at 0.002 mM
gallic acid
-
-
galloylpaeoniflorin
-
-
gemfibrozil
-
noncompetitive, IC50: 0.0065 mM, recombinant enzyme
gigantol
-
the binding of gigantol to aldose reductase is concentration-dependent and the maximum stoichiometric ratio of non-covalent bonding is 1:24.4. pH and temperature do not influence the interaction. Gigantol is protective against diabetic cataracts in rats induced by streptozotocin
glutathionyl-1,4-dihydroxynonene
-
i.e. GS-DHN, the mitogenic effects of HNE, but not GS-HNE or GSDHN, are abolished by glutathione depletion, stimulates protein kinase C, NF-kappaB, and AP-1, and increases cell growth in vascular smooth muscle cells
glutathionyl-4-hydroxynonenal
-
i.e. GS-HNE, the mitogenic effects of HNE, but not GS-HNE or GSDHN, are abolished by glutathione depletion, stimulates protein kinase C, NF-kappaB, and AP-1, and increases cell growth in vascular smooth muscle cells
glyceraldehyde
-
substrate inhibition
glycerol
-
uncompetitive to DL-glyceraldehyde
glycochenodeoxycholic acid
-
glycolithocholic acid
competitive inhibition with respect to geraniol
groenlandicine
hexanoic acid
-
competitive
Hexestrol
-
-
HgCl2
hydroxylamine
-
-
hypholomine B
IDD 594
IDD594
imirestat
-
-
indole-1-acetic acid
-
indomethacin
iodoacetamide
-
slight
iodoacetate
ionic detergents
-
-
-
isoliquiritigenin
isolithocholic acid
uncompetitive inhibition with respect to NADP+, competitive inhibition with respect to geraniol
isorhamnetin 3-O-beta-D-galactopyranoside
-
-
isorhamnetin 3-O-beta-D-glucopyranoside
-
-
jateorrhizine
-
12.68-14.08% inhibition at 0.05 mg/ml
kaempferol 3-O-rutinoside
-
KCl
0.5 M, 76% residual activity, 1 M, 37% residual activity
kuraridin
-
potent inhibitor of recombinant human aldose reductase
kurarinol
-
potent inhibitor of rat lens aldose reductase
kurarinone
-
potent inhibitor of rat lens aldose reductase
kushenol E
L-tyrosine
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
Li2SO4
lidorestat
liquiritigenin
lithocholic acid
competitive inhibition with respect to geraniol
lukianol B
-
IC50: 0.0006 mM
Ly-294002
-
0.05 mM, little decrease in sorbitol-induced activity
magnoflorine
-
18.33-29.85% inhibition at 0.05 mg/ml
malondialdehyde
-
at concentration above 0.8 mM substrate inhibition
Mandelic acid
-
competitive
Medroxyprogesterone acetate
-
less than 25% inhibition at 0.01 mM
methyl 2-(2-oxo-3-((3,4,5-trifluorophenyl)amino)quinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-((2,4-difluorophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-((4-bromo-2-fluorophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-((4-bromophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-((4-fluorophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-(4-bromo-2-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-(4-bromo-2-fluorophenoxy)-6-chloro-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-(4-bromo-2-fluorophenoxy)-6-fluoro-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-(4-bromo-2-fluorophenoxy)-7-chloro-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-(4-bromo-2-fluorophenoxy)-7-fluoro-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetat
-
-
methyl 2-(3-(4-bromophenoxy)-6-chloro-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-(4-bromophenoxy)-6-fluoro-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-(4-bromophenoxy)-7-chloro-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-(4-bromophenoxy)-7-fluoro-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(6-bromo-3-(4-bromo-2-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(6-bromo-3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(6-bromo-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(6-chloro-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(6-fluoro-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(7-bromo-3-(4-bromo-2-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(7-bromo-3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(7-bromo-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(7-chloro-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 2-(7-fluoro-3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate
-
-
methyl 3-methyl-2-([2-nitro-4-(trifluoromethyl)phenyl]amino)butanoate
-
methyl [(5Z)-2,4-dioxo-5-(3-phenoxybenzylidene)-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 5.88
methyl [(5Z)-5-(3-aminobenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 4.41
methyl [(5Z)-5-(3-methoxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 5.05
methyl [(5Z)-5-(3-methylbenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 5.00
methyl [(5Z)-5-(4-fluorobenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 4.89
methyl [(5Z)-5-(4-hydroxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 5.21
methyl [5-(3-methoxybenzyl)-2,4-dioxo-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 4.68
methyl {(5Z)-2,4-dioxo-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidin-3-yl}acetate
-
pIC50 is 4.54
methyl {(5Z)-2,4-dioxo-5-[4-(trifluoromethyl)benzylidene]-1,3-thiazolidin-3-yl}acetate
-
pIC50 is 5.46
Mg2+
-
10 mM inhibits complex formation of ALR 2 with alpha-crystallin, induces ALR 2 aggregation and precipitation
minalrestat
Morin hydrate
-
14.1% inhibition at 0.002 mM
mumeflavonoside A
-
-
mumeose K
-
-
mumeose L
-
-
mumeose M
-
-
mumeose N
-
-
myricetin
-
-
Myricitrin
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-beta-alanine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-alanine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-isoleucine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-leucine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-phenylalanine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-serine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-tyrosine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-valine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)glycine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)glycyl-L-phenylalanine
9% inhibition at 10.5 mM
N-(2-phenylethyl)-N-[(2-fluoro-4-bromophenyl)sulfonyl]glycine
-
-
N-(2-phenylethyl)-N-[(3-nitrophenyl)sulfonyl]glycine
-
-
N-(2-phenylethyl)-N-[(4-bromophenyl)sulfonyl]glycine
-
no inhibition of ALR1
N-(2-phenylethyl)-N-[(4-chlorophenyl)sulfonyl]glycine
-
no inhibition of ALR1
N-(2-phenylethyl)-N-[(4-fluorophenyl)sulfonyl]glycine
-
-
N-(2-phenylethyl)-N-[(4-methylphenyl)sulfonyl]glycine
-
no inhibition of ALR1
N-(2-phenylethyl)-N-[(4-nitrophenyl)sulfonyl]glycine
-
no inhibition of ALR1
N-(2-phenylethyl)-N-[(4-trifluoromethylphenyl)sulfonyl]glycine
-
no inhibition of ALR1
N-(2-phenylethyl)-N-{[4-(trifluoromethyl)phenyl]sulfonyl}glycine
-
-
N-(3,5-difluoro-4-hydroxyphenyl)-4-methoxybenzenesulfonamide
-
-
N-(3,5-difluoro-4-hydroxyphenyl)-4-nitrobenzenesulfonamide
-
-
N-(3,5-difluoro-4-hydroxyphenyl)benzenesulfonamide
-
compound exhibits high antioxidant potential. Determination of intestine permeability
N-(tert-butyl)-3-(4-(4-nitrobenzyl)-3-oxo-3,4-dihydroquinoxalin-2-ylacryl amide
-
N-acetyl-2,3-dihydrospiro[4H-thiopyrano[2,3-b]pyridin-4,4'imidazolidine]-2',5'-dione
-
50% inhibition at 0.050 mM
N-benzyl-N-[(2-fluoro-4-bromophenyl)sulfonyl]glycine
-
-
N-benzyl-N-[(2-naphthalenyl)sulfonyl]glycine
-
-
N-benzyl-N-[(3-nitrophenyl)sulfonyl]glycine
-
-
N-benzyl-N-[(4-bromophenyl)sulfonyl]glycine
-
no inhibition of ALR1
N-benzyl-N-[(4-chlorophenyl)sulfonyl]glycine
-
no inhibition of ALR1
N-benzyl-N-[(4-fluorophenyl)sulfonyl]glycine
-
-
N-benzyl-N-[(4-methylphenyl)sulfonyl]glycine
-
no inhibition of ALR1
N-benzyl-N-[(4-nitrophenyl)sulfonyl]glycine
-
no inhibition of ALR1
N-benzyl-N-[(4-trifluoromethylphenyl)sulfonyl]glycine
-
no inhibition of ALR1
N-cyclopropyl-N-[cyclopropyl(5-phenyl-1H-imidazol-2-yl)methyl]-2H-1-benzopyran-3-carboxamide
-
N-cyclopropyl-N-[cyclopropyl(5-phenyl-1H-imidazol-2-yl)methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-cyclopropyl-N-[cyclopropyl[5-(pyridin-3-yl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
-
N-cyclopropyl-N-[cyclopropyl[5-(pyridin-3-yl)-1H-imidazol-2-yl]methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-ethylmaleimide
N-galloyl beta-D-glucopyranosylamine
N-tert-butyl-2-(2-chloro-6-methoxy-4-([(3-methyl-5-sulfanyl-4H-1,2,4-triazol-4-yl)amino]methyl)phenoxy)acetamide
-
N-[(1S)-1-[5-(4-bromophenyl)-1H-imidazol-2-yl]-2-methylpropyl]-2H-1-benzopyran-3-carboxamide
-
N-[(1S)-1-[5-(4-bromophenyl)-1H-imidazol-2-yl]-2-methylpropyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-[(1S)-2-methyl-1-(5-phenyl-1H-imidazol-2-yl)propyl]-2H-1-benzopyran-3-carboxamide
-
N-[(5-phenyl-1H-imidazol-2-yl)methyl]-2H-1-benzopyran-3-carboxamide
-
N-[2-(2-thienyl)ethyl]-N-[(1,10-biphenyl)-4-sulfonyl]glycine
-
-
N-[2-(2-thienyl)ethyl]-N-[(1-naphthalenyl)sulfonyl]glycine
-
-
N-[2-(2-thienyl)ethyl]-N-[(2-fluoro-4-bromophenyl)sulfonyl]glycine
-
-
N-[2-(2-thienyl)ethyl]-N-[(2-naphthalenyl)sulfonyl]glycine
-
-
N-[2-(2-thienyl)ethyl]-N-[(3-nitrophenyl)sulfonyl]glycine
-
-
N-[2-(2-thienyl)ethyl]-N-[(4-bromophenyl)sulfonyl]glycine
-
-
N-[2-(2-thienyl)ethyl]-N-[(4-chlorophenyl)sulfonyl]glycine
-
no inhibition of ALR1
N-[2-(2-thienyl)ethyl]-N-[(4-fluorophenyl)sulfonyl]glycine
-
-
N-[2-(2-thienyl)ethyl]-N-[(4-nitrophenyl)sulfonyl]glycine
-
-
N-[2-(2-thienyl)ethyl]-N-[(4-trifluoromethylphenyl)sulfonyl]glycine
-
-
N-[2-(2-thienyl)ethyl]-N-[(5-dimethylamino-1 naphthalenyl)sulfonyl]glycine
-
-
N-[2-(2-thienyl)ethyl]-N-[(5-dimethylamino-1-naphthalenyl)sulfonyl]glycine
-
-
N-[[5-(4-bromophenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-bromophenyl)-1H-imidazol-2-yl]methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-chlorophenyl)-1H-imidazol-2-yl](cyclopropyl)methyl]-N-cyclopropyl-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-chlorophenyl)-1H-imidazol-2-yl](cyclopropyl)methyl]-N-cyclopropyl-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-chlorophenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-chlorophenyl)-1H-imidazol-2-yl]methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-methoxyphenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
-
N-[[6-methoxy-5(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-N-methylglycine
N2-(2-methylaminobenzoyl)tetrahydro-1H-pyrido[3,4-b]indol-1-one
-
i.e. rhetsinine, from Evodia rutaecarpa hot water extract. Rhetsinine inhibits sorbitol accumulation by 79.3% at 0.1 mM in erythrocytes
NADP+
NaNO3
-
-
naphtho[1,2-d]isothiazole acetic acid derivatives
-
-
naringenin
uncompetitive. The interaction is enthalpy driven and the microenvironment of aromatic residues is also altered. Naringenin inhibits fructosamine content by approximately 31.6% at 0.01 mM, and more than 93% inhibition of fluorescent advanced glycation end-products is achieved. Naringenin forms hydrogen bonds (Asn160 and Ile260), and two Pi-Pi interactions with Trp20 and one with His110
nitazoxanide
-
partial inhibition
nitric oxide
nudanpinoside H
-
-
Octanoate
-
-
oxaloacetate
-
-
oxypaeoniflorin
-
-
p-Carboxybenzaldehyde
-
substrate inhibition at higher concentration
p-catechuic acid
-
-
p-chloromercuribenzoate
p-coumaric acid
-
-
p-hydroxymercuribenzoate
p-nitrobenzaldehyde
-
at concentration above 2 mM substrate inhibition
paeoniflorigenone
-
-
paeoniflorin
-
-
paeonolide
-
-
paeonoside
-
-
palbinone
-
-
palmatine iodide
-
50% inhibition at 68 nM
palmatine sulfate
-
50% inhibition at 51.78 nM
PD-98059
-
0.05 mM, decrease of sorbitol-induced activity to control level
pentagalloyl glucose
-
46.6% inhibition at 0.002 mM
Phenobarbital
Phenobarbitone
-
-
phenylacetic acid
-
competitive
pioglitazone
-
-
piplartine
-
-
ponalrestat
protocatechuic acid
-
12.6% inhibition at 0.002 mM
puerariafuran
-
a 2-arylbenzofuran from Pueraria lobata, collected in Kyonggi-do, Seongnam, Kyungwon University, Korea. Xylose-induced opacity of lenses is significantly improved when treated with puerariafuran
pyrazole
-
slight
pyrazolo[5,1-c][1,2,4]benzotriazin-8-yl dimethylcarbamate
EN-00263
pyrid-3-ylcarbinol
-
-
pyridoxal 5'-phosphate
quercetin
quercetin 3-O-(2''-O-acetyl)-beta-D-glucopyranoside
-
-
quercetin 3-O-(6''-O-acetyl)-beta-D-glucopyranoside
-
-
quercetin 3-O-(6''-O-benzoyl)-beta-D-galactopyranoside
-
-
quercetin 3-O-beta-D-apiofuranosyl-(1->2)-beta-D-glucopyranoside
-
quercitrin
ranirestat
-
-
rhamnocitrin-3-O-rhamnoside
-
rosiglitazone
-
-
rosmarinic acid
docking structure with ALR2, overview
rubrolide L
-
-
rutin
S-nitroso-N-acetylpenicillamine
-
1 mM, 86% inhibition, reversed by incubation with fresh media
S-nitrosoglutathione
S-nitrosoglutathione monoethylester
-
1 mM, 73% inhibition, reversed by incubation with fresh media
S12728
-
inhibitor of ALR2, but no inhibition of ALR1
SB-203580
-
0 0.01 mM, decrease of sorbitol-induced activity below control level
semilicoisoflavone B
silibinin
-
-
silymarin
-
-
sorbinil
sorbitol
-
competitive inhibition with NADP+ and glucose
Statil
molecular modeling redicts an enhancement of net binding energy of the complex by 33% through replacement of the fluorine atom of statil by a carboxylate group
stobadine
-
i.e. (-)-cis-2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3,-b]indole
sulfhydryl inhibitors
-
-
-
sulfuretin
-
69.8% inhibition at 0.002 mM
sulindac
exhibits both the highest inhibitory activity towards human aldose reductase among popular non-steroidal anti-inflammatory drugs and clear beneficial clinical effects on Type 2 diabetes, uncompetitive inhibition, enzyme binding structure, overview
sulindac sulfide
enzyme binding structure, overview
sulindac sulfone
enzyme binding structure, overview
syringic acid
-
-
tetramethylene glutaric acid
-
-
thienocinnolinone alkanoic acid derivatives
-
i.e. 8-halogen-4,4a-5,6-tetrahydrothieno[2,3-h]cinnolinone-N2-alkanoic acid derivatives, synthesis and inhibitory potency, IC50 as low as 0.0314 mM, the length of the N2 alkanoic chain strongly influences the inhibitory activity, overview
-
tizoxanide
-
partial inhibition
TNF-alpha
-
-
-
Tolmetin
enzyme binding structure, overview
Tolrestat
trans-cinnamic acid
-
-
Valproate
-
less than 25% inhibition at 0.5 mM
Valproic acid
vanillic acid
zearalenone
-
-
Zenarestat
zofenoprilat-glutathione disulfide
-
the enzyme is specifically S-thionylated and inactivated by ZSSG, a homodisulfide formed by GSH and zofenoprilat, an angiotensin-converting enzyme inhibitor carrying a thiol group, which is more stable than glutathione, optimization, overview
zopolrestat
[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino](phenyl)acetic acid
-
[(2E)-2-[2-(carboxymethyl)hydrazinylidene]-3-[[4-(trifluoromethyl)phenyl]methyl]-2,3-dihydro-1H-benzimidazol-1-yl](oxo)acetic acid
-
[(3-[[(3-nitrophenyl)methyl]carbamoyl][1,1'-biphenyl]-4-yl)oxy]acetic acid
-
[(5H-[1,2,4]triazino[5,6-b]indol-3-yl)sulfanyl]acetic acid
-
[(5Z)-2,4-dioxo-5-(3-phenoxybenzylidene)-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.89
[(5Z)-2,4-dioxo-5-(4-phenoxybenzylidene)-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.09
[(5Z)-5-(3-fluorobenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.13
[(5Z)-5-(3-hydroxy-4-methoxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.25
[(5Z)-5-(3-hydroxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.18
[(5Z)-5-(3-methoxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.32
[(5Z)-5-(3-methylbenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.19
[(5Z)-5-(3-nitrobenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.31
[(5Z)-5-(4-fluorobenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 5.94
[(5Z)-5-(4-hydroxy-3-methoxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.15
[(5Z)-5-(4-hydroxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.82
[(5Z)-5-(biphenyl-4-ylmethylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.59
[(5Z)-5-(naphthalen-1-ylmethylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.77
[(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
-
[2,4-dioxo-5-(3-phenoxybenzyl)-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.00
[2,4-dioxo-5-(3-phenoxybenzyl)thiazolidin-3-yl]acetic acid
-
IC50: 0.0010 mM
[2,4-dioxo-5-(3-phenoxybenzyl)thiazolidin-3-yl]acetic acid methyl ester
-
26% inhibition of ALR2 at 0.05 mM
[2,4-dioxo-5-(4-phenoxybenzyl)-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 5.55
[2,4-dioxo-5-(4-phenoxybenzyl)thiazolidin-3-yl]acetic acid
-
IC50: 0.0028 mM
[2,4-dioxo-5-(4-phenoxybenzylidene)thiazolidin-3-yl]acetic acid
-
IC50: 0.00082 mM
[2,4-dioxo-5-(4-phenoxybenzylidene)thiazolidin-3-yl]acetic acid methyl ester
-
33% inhibition of ALR2 at 0.05 mM
[2-(ethynylcarbamoyl)-5-fluorophenoxy]acetic acid
the ligand exhibits a terminal pi-electron rich substituent at the amide function, which fills the cleft between Leu300 and Trp219 next to the sealed specificity pocket
[2-oxo-3-(2-phenylethyl)quinoxalin-1(2H)-yl]acetic acid
-
[2-oxo-3-[(Z)-2-phenylethenyl]quinoxalin-1(2H)-yl]acetic acid
-
[2-oxo-8-[(E)-2-phenylethenyl]-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
9fold selectivity for ALR2 over ALR1
[2-[(1,3-benzothiazol-2-yl)carbamoyl]-5-fluorophenoxy]acetic acid
an H-bond is formed between the backbone Leu300NH group and the nitrogen atom of the benzothiazolyl moiety
[2-[(2-carbamoylphenyl)methyl]-3-oxo-2,3-dihydro-5H-[1,2,4]triazino[5,6-b]indol-5-yl]acetic acid
-
424fold selectivity for ALR2 over ALR1
[2-[(2-cyanophenyl)methyl]-3-oxo-2,3-dihydro-5H-[1,2,4]triazino[5,6-b]indol-5-yl]acetic acid
-
1333fold selectivity for ALR2 over ALR1
[3,4-dioxo-10-[[4-(trifluoromethyl)phenyl]methyl]-3,4-dihydro[1,2,4]triazino[4,3-a]benzimidazol-2(10H)-yl]acetic acid
-
[3-(2,2-dimethylpropanoyl)-1H-indol-1-yl]acetic acid
-
[3-(2,4-dihydroxyphenyl)-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-(2,5-dihydroxyphenyl)-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
-
-
[3-[(4-chlorophenyl)methyl]-1,2,4-oxadiazol-5-yl]acetic acid
-
[3-[(diethylamino)methyl]-1H-indol-1-yl]acetic acid
-
[3-[(dimethylamino)methyl]-2-methyl-1H-indol-1-yl]acetic acid
-
[3-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-6-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
most potent activity
[3-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-6-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[(E)-2-(4-hydroxyphenyl)ethenyl]-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[(E)-2-(4-hydroxyphenyl)ethenyl]-6-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[(E)-2-(4-hydroxyphenyl)ethenyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
most active inhibitor evaluated
[3-[(E)-2-(4-methoxyphenyl)ethenyl]-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[(morpholin-4-yl)methyl]-1H-indol-1-yl]acetic acid
-
[3-[(propan-2-yl)sulfanyl]-5H-[1,2,4]triazino[5,6-b]indol-5-yl]acetic acid
-
[3-[(pyrrolidin-1-yl)methyl]-1H-indol-1-yl]acetic acid
-
[3-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-6-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[2-(4-hydroxyphenyl)ethyl]-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[2-(4-hydroxyphenyl)ethyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[5-(3-aminobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid methyl ester
-
IC50: 0.039 mM
[5-(3-carboxymethoxy-4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid
i.e. CMD, a potent inhibitor of ALR2, but not for ALR1, structure molecular modelling, overview. The non-conserved C-terminal residue Leu300 in ALR2, which is Pro301 in ALR1, contributes to inhibitor selectivity
[5-(3-hydroxy-4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid
i.e. HMD, modelling of inhibitor-enzyme active site complex
[5-(3-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid
-
IC50: 0.00066 mM
[5-(3-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid methyl ester
-
43% inhibition of ALR2 at 0.05 mM
[5-(3-methoxybenzyl)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 5.53
[5-(3-methoxybenzyl)-2,4-dioxothiazolidin-3-yl]acetic acid
-
IC50: 0.0030 mM
[5-(3-methoxybenzyl)-2,4-dioxothiazolidin-3-yl]acetic acid methyl ester
-
IC50: 0.0211 mM
[5-(3-nitrobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid
-
IC50: 0.00049 mM
[5-(3-nitrobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid methyl ester
-
22% inhibition of ALR2 at 0.05 mM
[5-(4-aminobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid methyl ester
-
25% inhibition of ALR2 at 0.05 mM
[5-(4-benzyloxybenzyl)-2,4-dioxothiazolidin-3-yl]acetic acid methyl ester
-
24% inhibition of ALR2 at 0.05 mM
[5-(4-benzyloxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid
-
IC50: 0.00028 mM
[5-(4-benzyloxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid methyl ester
-
12% inhibition of ALR2 at 0.05 mM
[5-(4-bromophenyl)-3-methyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
-
[5-(4-chlorophenyl)-1-oxo-3-propylpyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
18fold selectivity for isoform AKR1B1 over AKR1B10
[5-(4-chlorophenyl)-3-ethyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
39fold selectivity for isoform AKR1B1 over AKR1B10
[5-(4-chlorophenyl)-3-ethyl-9-fluoro-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
9fold selectivity for isoform AKR1B1 over AKR1B10
[5-(4-chlorophenyl)-3-methyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
37fold selectivity for isoform AKR1B1 over AKR1B10
[5-(4-chlorophenyl)-9-fluoro-3-methyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
3fold selectivity for isoform AKR1B1 over AKR1B10
[5-(4-hydroxybenzyl)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 5.68
[5-(4-hydroxybenzyl)-2,4-dioxothiazolidin-3-yl]acetic acid
-
IC50: 0.0021 mM
[5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid
-
IC50: 0.00015 mM
[5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid methyl ester
-
IC50: 0.0062 mM
[5-(4-methoxybenzyl)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 5.97
[5-(4-methoxybenzyl)-2,4-dioxothiazolidin-3-yl]acetic acid
-
IC50: 0.0011 mM
[5-(4-methoxybenzyl)-2,4-dioxothiazolidin-3-yl]acetic acid methyl ester
-
24% inhibition of ALR2 at 0.05 mM
[5-(4-nitrobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid
-
IC50: 0.0012 mM
[5-(4-nitrobenzylidene)-2,4-dioxothiazolidin-3-yl]-acetic acid methyl ester
-
8% inhibition of ALR2 at 0.05 mM
[5-(biphenyl-4-ylmethyl)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 5.77
[5-fluoro-2-(phenylcarbamoyl)phenoxy]acetic acid
ligand is among the weakest of the known ALR2 binders that open the specificity pocket
[5-fluoro-2-[(3-nitrophenyl)carbamoyl]phenoxy]acetic acid
the ligand opens the specificity pocket with its terminal benzyl moiety and places the meta attached nitro group deeply in the transient pocket
[5-fluoro-2-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)carbamoyl]phenoxy]acetic acid
-
[5-fluoro-2-[[[(4,5,7-trifluoro-2-benzothiazolyl)methyl]amino]carbonyl]phenoxy]acetic acid
-
[5-methyl-7-oxo-4-(2-phenylethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl]acetic acid
-
[6-ethyl-3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
-
-
[6-hydroxy-3-(4-hydroxyphenoxy)pyrazin-2-yl](4-hydroxyphenyl)methanone
-
isolated from red ascidian Botryllus leachi, pyrazine derivative, IC50: 0.0194 mM
[6-methoxy-2-oxo-3-(2,4,6-trihydroxyphenyl)quinoxalin-1(2H)-yl]acetic acid
-
[6-methyl-3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
-
-
[7-fluoro-3-[(E)-2-(4-hydroxyphenyl)ethenyl]-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[7-fluoro-3-[2-(4-hydroxyphenyl)ethyl]-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[7-methoxy-2-oxo-3-(2,4,6-trihydroxyphenyl)quinoxalin-1(2H)-yl]acetic acid
-
[7-methoxy-2-oxo-3-[(E)-2-phenylethenyl]quinoxalin-1(2H)-yl]acetic acid
-
[8-(4-formylphenyl)-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
-
[8-(4-methoxyphenyl)-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
-
[8-[(E)-2-(4-fluorophenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
25.7fold selectivity for ALR2 over ALR1
[8-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
24fold selectivity for ALR2 over ALR1
[8-[(E)-2-(4-hydroxyphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
60fold selectivity for ALR2 over ALR1
[8-[(E)-2-(4-methoxyphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
-
[8-[(E)-2-(4-methylphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
-
[8-[(E)-2-(4-nitrophenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
-
[8-[(E)-2-(4-tert-butylphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
4fold selectivity for ALR2 over ALR1
[8-[(E)-2-([1,1'-biphenyl]-4-yl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
-
[9-fluoro-5-(4-methoxyphenyl)-3-methyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
9fold selectivity for isoform AKR1B1 over AKR1B10
[[(4-methylphenyl)sulfonyl](2-thiophen-2-ylethyl)amino]acetic acid
S-12728
{(5Z)-2,4-dioxo-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 6.33
{(5Z)-2,4-dioxo-5-[4-(trifluoromethyl)benzylidene]-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 6.34
{(5Z)-5-[3-(carboxymethoxy)-4-ethoxybenzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 5.85
{(5Z)-5-[3-(carboxymethoxy)benzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 6.64
{(5Z)-5-[4-(benzyloxy)benzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 6.55
{(5Z)-5-[4-(carboxymethoxy)-3-methoxybenzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 6.59
{(5Z)-5-[4-(carboxymethoxy)benzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 6.22
additional information
-